AKT1 and prostate carcinoma: Due to the challenges of low solubility in the water-like solvent of Wortmannin, other Akt inhibitors being used in clinical trials for prostate cancer include capivasertib, an oral pan-Akt inhibitor, and ipatasrtib, another oral small compound that binds to the ATP-binding site of Akt [56,57].